A number of pharmaceutical industries have developed selective α7 nAChR agonists for the treatment of neuropsychiatric diseases, including schizophrenia and Alzheimer's disease, and clinical trials of some drugs have been started. The gene discussed is CHRNA7; the disease is early-onset autosomal dominant Alzheimer disease.